Colorectal cancer and brain metastases: An aggressive disease with a different response to treatment

• Published in: Tumori 2019-10, Vol.105 (5), p.427-433
• Main Authors: Chahine, Georges, Ibrahim, Tony, Felefly, Tony, El-Ahmadie, Abir, Freiha, Pamela, El-Khoury, Lionel, Khalife-Saleh, Nadine, Saleh, Khalil
• Format: Article
• Language: English
• Subjects: Adult; Aged; Brain Neoplasms - epidemiology; Brain Neoplasms - pathology; Brain Neoplasms - secondary; Colorectal Neoplasms - epidemiology; Colorectal Neoplasms - pathology; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Retrospective Studies
• ISSN: 0300-8916; 2038-2529
• DOI: 10.1177/0300891618765541

Introduction: Brain metastases (BM) are rare in colorectal cancer (CRC) and are associated with a dismal prognosis. This work aims to report the rate of BM in CRC patients treated in a single institution, along with survival and prognostic factors. Methods: Medical charts for patients with histologically proven CRC were retrospectively reviewed. Results: A total of 538 patients were identified, of whom 33% developed any metastatic disease and 4.4% presented BM. Lung was the most frequently associated metastatic site (in 68% of the cases). The only factor independently associated with BM development was the presence of metastatic disease at the time of initial presentation. The median duration from initial diagnosis to BM development was 38.6 months (SD 29.1 months). Median survival after BM development was 62 days (95% confidence interval [CI] 56–68). Patients diagnosed with BM within 1 year of cancer diagnosis responded significantly better to treatment than those who acquired BM later, with a median survival after BM diagnosis of 261 days versus 61 days, respectively (p = .002). Patients with BM who received antiangiogenic therapy had an improved median survival compared to those who did not (151 days vs 59 days, p = 0.02; hazard ratio for death 0.29 [95% CI 0.09–0.94]). Conclusion: CRC with BM is an aggressive disease resistant to standard treatment and is associated with poor outcomes. Adding antiangiogenic therapy might be of value for those patients. Patients with BM developing early in the disease course might respond better to treatment.